Protara Therapeutics, Inc. (TARA) – What Are Brokerages Thinking About This Stock?

Protara Therapeutics, Inc. (NASDAQ:TARA) has earned an average rating of “Moderate Buy” from the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and seven have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $26.25.

Several brokerages have commented on TARA. Cantor Fitzgerald reissued an “overweight” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Thursday, October 15th. Finally, Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, September 5th.

Hedge Funds Weigh In On Protara Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. WINTON GROUP Ltd increased its holdings in shares of Protara Therapeutics by 16.7% during the second quarter. WINTON GROUP Ltd now owns 32,800 shares of the company’s stock worth $125,000 after buying an additional 4,700 shares in the last quarter. Squarepoint Ops LLC bought a new position in shares of Protara Therapeutics in the 2nd quarter valued at $69,000. Corient Private Wealth LP bought a new position in shares of Protara Therapeutics in the 2nd quarter valued at $41,000. Velan Capital Investment Management LP lifted its stake in shares of Protara Therapeutics by 0.4% in the 2nd quarter. Velan Capital Investment Management LP now owns 2,844,652 shares of the company’s stock valued at $10,867,000 after acquiring an additional 10,000 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in shares of Protara Therapeutics during the 2nd quarter valued at $113,000. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Stock Performance

Protara Therapeutics stock opened at $2.33 on Friday. Protara Therapeutics has a 52 week low of $2.28 and a 52 week high of $7.82. The stock has a market capitalization of $137.70 million, a P/E ratio of -1.73 and a beta of 1.47. The stock has a fifty day moving average of $3.34 and a 200-day moving average of $4.08.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.36) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.03). On average, research analysts forecast that Protara Therapeutics will post -1.40 earnings per share for the current year.

About Protara Therapeutics

Protara Therapeutics, Inc is a clinical-stage biotechnology company focused on developing transformative therapies for cancer and other serious diseases. The company’s lead product candidate, TARA-002, is an investigational cell-based immunotherapy derived from a proprietary preparation of Streptococcus pyogenes. Protara is evaluating TARA-002 primarily for the treatment of non-muscle-invasive bladder cancer.

Protara has also investigated TARA-002 for lymphatic malformations, rare abnormalities of the lymphatic system that can cause swelling, pain and other complications.